House Oversight Committee digs in on McKinsey’s conflicting ties with FDA, opioids, and blocking Humira competitors

McKinsey is under fire again, this time from the House Oversight Committee, which is digging into the consulting firm’s close ties to the FDA while working simultaneously to promote opioids and find ways to stall competition for AbbVie’s blockbuster rheumatoid arthritis drug Humira.

Since 2008, FDA has paid McKinsey over...

Click to view original post